Patient profles as an aim to optimize selection in the second line setting: the role of afibercept

• B. González Astorga ^[7] ; F. Salvà Ballabrera ^[1] ; E. Aranda Aguilar ^[2] ; E. Élez Fernández ^[1] ; P. García Alfonso ^[3] ; E. González Flores ^[4] ; R. Vera García ^[8] ; A. Fernández Montes ^[9] ; A. M. López Muñoz ^[5] ; A. Salud Salvia ^[6]
  1. [1] Hospital Vall d'Hebron

     Hospital Vall d'Hebron

     Barcelona, España

     
  2. [2] Hospital Universitario Reina Sofia

     Hospital Universitario Reina Sofia

     Cordoba, España

     
  3. [3] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  4. [4] Hospital Universitario Virgen de las Nieves

     Hospital Universitario Virgen de las Nieves

     Granada, España

     
  5. [5] Complejo Asistencial Universitario de Burgos

     Complejo Asistencial Universitario de Burgos

     Burgos, España

     
  6. [6] Hospital Universitario Arnau de Vilanova

     Hospital Universitario Arnau de Vilanova

     Lérida, España

     
  7. [7] Hospital Universitario Clínico San Cecilio, Granada, Spain
  8. [8] Complejo Hospitalario de Navarra, Navarra, Spain
  9. [9] Complexo Hospitalario de Ourense, Ourense, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 8, 2021, págs. 1520-1528
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Colorectal cancer is the second leading cause of cancer-related death worldwide. For metastatic colorectal cancer (mCRC) patients, it is recommended, as frst-line treatment, chemotherapy (CT) based on doublet cytotoxic combinations of fuorouracil, leucovorin, and irinotecan (FOLFIRI) and fuorouracil, leucovorin, and oxaliplatin (FOLFOX). In addition to CT, biological (targeted agents) are indicated in the frst-line treatment, unless contraindicated. In this context, most of mCRC patients are likely to progress and to change from frst line to second line treatment when they develop resistance to frst-line treatment options. It is in this second line setting where Afibercept ofers an alternative and efective therapeutic option, thought its specifc mechanism of action for diferent patient’s profle: RAS mutant, RAS wild-type (wt), BRAF mutant, potentially resectable and elderly patients. In this paper, a panel of experienced oncologists specialized in the management of mCRC experts have reviewed and selected scientifc evidence focused on Afibercept as an alternative treatment.